These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19122356)

  • 1. A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia.
    Seki M; Higashiyama Y; Imamura Y; Nakamura S; Kurihara S; Izumikawa K; Kakeya H; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
    Intern Med; 2009; 48(1):49-55. PubMed ID: 19122356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.
    Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Mizuta Y; Tsukamoto K; Kohno S
    Intern Med; 2006; 45(17):995-9. PubMed ID: 17015999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
    Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
    J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
    Okimoto N; Kurihara T; Honda N; Asaoka N; Fujita K; Ohba H; Nakamura J
    J Infect Chemother; 2003 Jun; 9(2):183-6. PubMed ID: 12825120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulbactam/ampicillin combination in the treatment of acute and chronic lower respiratory infections.
    Bisetti A; Grassi L; Scacciacillani E; Putti P
    J Int Med Res; 1991; 19 Suppl 1():36A-43A. PubMed ID: 2060692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
    Soto E; Shoji S; Muto C; Tomono Y; Marshall S
    Br J Clin Pharmacol; 2014 Mar; 77(3):509-21. PubMed ID: 24102758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
    Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
    J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ampicillin/sulbactam for children hospitalized with community-acquired pneumonia.
    Tapısız A; Özdemir H; Çiftçi E; Belet N; Ince E; Doğru Ü
    J Infect Chemother; 2011 Aug; 17(4):504-9. PubMed ID: 21258955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
    Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
    J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
    Castagnola E; Bandettini R; Ginocchio F; Perotti M; Masa DL; Ciucci A; Loy A; Caviglia I; Haupt R; Guida E; Pini Prato A; Mattioli G; Buffa P
    J Chemother; 2013 Aug; 25(4):213-6. PubMed ID: 23906074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.
    Williams D; Perri M; Zervos MJ
    Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):293-8. PubMed ID: 8070432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
    Harkless L; Boghossian J; Pollak R; Caputo W; Dana A; Gray S; Wu D
    Surg Infect (Larchmt); 2005; 6(1):27-40. PubMed ID: 15865549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.
    Majcher-Peszynska J; Loebermann M; Klammt S; Frimmel S; Mundkowski RG; Welte T; Reisinger EC; Drewelow B;
    Infection; 2014 Feb; 42(1):79-87. PubMed ID: 23904004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sulbactam-ampicillin monotherapy in the ambulatory treatment of pneumonia. Results of mono-administration].
    Natale F; Altafini A; Donno GD; Facchi S
    Clin Ter; 1998; 149(2):151-4. PubMed ID: 9780482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract.
    Geckler RW
    Clin Ther; 1994; 16(4):662-72. PubMed ID: 7982254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Lin HS; Lee MH; Cheng CW; Hsu PC; Leu HS; Huang CT; Ye JJ
    Infect Dis (Lond); 2015 Jun; 47(6):370-8. PubMed ID: 25746600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam).
    Coccolini F; Catena F; Ansaloni L; Ercolani G; Di Saverio S; Gazzotti F; Lazzareschi D; Pinna AD
    BMC Gastroenterol; 2011 Apr; 11():42. PubMed ID: 21501482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia in Japan.
    Yamamoto Y; Watanabe A; Goto H; Matsushima T; Abe S; Aoki N; Shimokata K; Mikasa K; Niki Y; Kohno S
    J Infect Chemother; 2012 Aug; 18(4):544-51. PubMed ID: 22618270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
    Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY
    Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].
    Karaboğa B; Çilli A
    Tuberk Toraks; 2015 Jun; 63(2):94-101. PubMed ID: 26167966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.